The Antiphospholipid Syndrome as a Neurological Disease

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 2, 2010, Pages 97-108

  Arnson, Yoav ^a   Shoenfeld, Yehuda ^b   Alon, Eisen ^a   Amital, Howard ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid antibodies; APS; Cerebrovascular accidents; Migraines; Seizures

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HALOPERIDOL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; RITUXIMAB; WARFARIN;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; B CELL LYMPHOMA; BEHAVIOR DISORDER; BRAIN ISCHEMIA; CHOREA; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DRUG WITHDRAWAL; DYSTONIA; EPILEPSY; HEADACHE; HUMAN; HYPERACTIVITY; HYPERLIPIDEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRACRANIAL HYPERTENSION; LIVEDO RETICULARIS; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; NONHUMAN; OPTIC NERVE DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; VASCULITIS; VEIN THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; INTRACRANIAL THROMBOSIS; NERVOUS SYSTEM DISEASES; PROTEIN BINDING; PUBMED;

EID: 77955655820     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.05.001     Document Type: Review

References (204)

1. Hughes G.R. The antiphospholipid syndrome: ten years on. Lancet 1993, 342:341-344.
2. Bertolaccini M.L., Khamashta M.A., Hughes G.R. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005, 1:40-46.
3. Hughes G.R. The anticardiolipin syndrome. Clin Exp Rheumatol 1985, 3:285-286.
4. Lowy I. Scientific facts and their public: the history of the diagnosis of syphilis. Rev Synth 1995, 116:27-54.
5. Conley C.L., Rathbun H.K., Orse W.I., Onibson J.E. Circulating anticoagulants as a cause of hemorrhagic diathesis in man. Bull Johns Hopkins Hosp 1948, 83:288-293.
6. McIntyre J.A., Wagenknecht D.R., Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection-an overview. Am J Reprod Immunol 1997, 37:101-110.
7. Shan H., Goldman J., Cunto G., Manuppello J., Chaiken I., Cines D.B., et al. Heterogeneity of anti-phospholipid and anti-endothelial cell antibodies. J Autoimmun 1998, 11:651-660.
8. Shoenfeld Y., Twig G., Katz U., Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008, 30:74-83.
9. Wilson W.A. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001, 27:499-505. v.
10. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295:1050-1057.
11. Roubey R.A. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998, 7(Suppl 2):S114-S119.
12. Pierangeli S.S., Chen P.P., Gonzalez E.B. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006, 13:366-375.
13. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997-2002.
14. Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vazquez J.J., et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988, 47:849-854.
15. Campbell A.L., Pierangeli S.S., Wellhausen S., Harris E.N. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995, 73:529-534.
16. Vismara A., Meroni P.L., Tincani A., Harris E.N., Barcellini W., Brucato A., et al. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988, 74:247-253.
17. Harris E.N., Pierangeli S.S. Functional effects of anticardiolipin antibodies. Lupus 1996, 5:372-377.
18. Marciniak E., Romond E.H. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989, 74:2426-2432.
19. Cabiedes J., Cabral A.R., Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995, 22:1899-1906.
20. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
21. Muller S., Dieker J., Tincani A., Meroni P.L. Pathogenic anti-nucleosome antibodies. Lupus 2008, 17:431-436.
22. Meroni P.L., Tincani A., Sepp N., Raschi E., Testoni C., Corsini E., et al. Endothelium and the brain in CNS lupus. Lupus 2003, 12:919-928.
23. Abbott N.J., Mendonca L.L., Dolman D.E. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003, 12:908-915.
24. Espinosa G., Cervera R., Font J., Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003, 2:86-93.
25. Trysberg E., Nylen K., Rosengren L.E., Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003, 48:2881-2887.
26. Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
27. Sun K.H., Liu W.T., Tsai C.Y., Liao T.S., Lin W.M., Yu C.L. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis 1992, 51:707-712.
28. Ball-Rosen C., Primak-Rubinovicz H., Korczyn A.D., Wang N., Farchi A., Shavit S., et al. Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann NY Acad Sci 2007, 1109:473-483.
29. Khalili A., Cooper R.C. A study of immune responses to myelin and cardiolipin in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991, 85:365-372.
30. Oosting J.D., Derksen R.H., Hackeng T.M., van V.M., Preissner K.T., Bouma B.N., et al. In vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991, 66:666-671.
31. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
32. Riccio A., Andreassi C., Eboli M.L. Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors. Neurosci Lett 1998, 257:116-118.
33. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004, 11:67-75.
34. Smith H.R., Hansen C.L., Rose R., Canoso R.T. Autoimmune MRL-1 pr/1pr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990, 17:911-915.
35. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., et al. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res 2006, 169:289-293.
36. Pierangeli S.S., Harris E.N. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993, 93:269-272.
37. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994, 7:441-455.
38. Haj-Yahia S., Sherer Y., Blank M., Kaetsu H., Smolinsky A., Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 2003, 12:364-369.
39. Brey R.L., Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998, 7(Suppl 2):S67-S74.
40. Sanna G., Bertolaccini M.L., Cuadrado M.J., Khamashta M.A., Hughes G.R. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003, 42:200-213.
41. Harris E.N., Gharavi A.E., Kworth-Young C.G., Patel B.M., Derue G., Hughes G.R. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985, 44:281-283.
42. Harris E.N., Englert H., Derve G., Hughes G.R., Gharavi A. Antiphospholipid antibodies in acute Guillain-Barre syndrome. Lancet 1983, 2:1361-1362.
43. Asherson R.A., Mercey D., Phillips G., Sheehan N., Gharavi A.E., Harris E.N., et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987, 46:605-611.
44. Chapman J., Shoenfeld Y. Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. Ann NY Acad Sci 2002, 966:415-424.
45. Levine S.R., Welch K.M. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987, 44:876-883.
46. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von L.P., et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004, 31:1344-1348.
47. Miesbach W., Gilzinger A., Gokpinar B., Claus D., Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg 2006, 108:135-142.
48. Krause I., Leibovici L., Blank M., Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007, 16(3):176-180.
49. Shah N.M., Khamashta M.A., Atsumi T., Hughes G.R. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998, 7:3-6.
50. Montalban J., Rio J., Khamastha M., Davalos A., Codina M., Swana G.T., et al. Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke 1994, 25:2412-2415.
51. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
52. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990, 21:1268-1273. The Antiphospholipid Antibodies in Stroke Study Group.
53. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
54. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
55. Levine S.R., Deegan M.J., Futrell N., Welch K.M. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990, 40:1181-1189.
56. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32:1701-1706.
57. Krause I., Lev S., Fraser A., Blank M., Lorber M., Stojanovich L., et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005, 64:1490-1493.
58. Champion R.H., Rook A. Livedo reticularis. Proc R Soc Med 1960, 53:961-962.
59. Schellong S.M., Weissenborn K., Niedermeyer J., Wollenhaupt J., Sosada M., Ehrenheim C., et al. Classification of Sneddon's syndrome. Vasa 1997, 26:215-221.
60. Briley D.P., Coull B.M., Goodnight S.H. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989, 25:221-227.
61. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
62. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von L.P., et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004, 31:1344-1348.
63. Cimaz R., Meroni P.L., Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006, 15:191-197.
64. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
65. Silverman I.E., Restrepo L., Mathews G.C. Poststroke seizures. Arch Neurol 2002, 59:195-201.
66. Eriksson K., Peltola J., Keranen T., Haapala A.M., Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001, 46:129-137.
67. Verrot D., San-Marco M., Dravet C., Genton P., Disdier P., Bolla G., et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997, 103:33-37.
68. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von L.P., et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004, 31:1344-1348.
69. Weingarten K., Filippi C., Barbut D., Zimmerman R.D. The neuroimaging features of the cardiolipin antibody syndrome. Clin Imaging 1997, 21:6-12.
70. Hilker R., Thiel A., Geisen C., Rudolf J. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 2000, 9:311-316.
71. Chapman J., Soloveichick L., Shavit S., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol 2005, 12:175-180.
72. Liou H.H., Wang C.R., Chou H.C., Arvanov V.L., Chen R.C., Chang Y.C., et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994, 54:1119-1125.
73. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000, 11:36-38.
74. Jacobson M.W., Rapport L.J., Keenan P.A., Coleman R.D., Tietjen G.E. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol 1999, 21:251-264.
75. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000, 11:36-38.
76. Juby A., Davis P., Genge T., McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 1995, 4:482-485.
77. Chapman J., Rand J.H., Brey R.L., Levine S.R., Blatt I., Khamashta M.A., et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003, 12:514-517.
78. Denburg S.D., Carbotte R.M., Ginsberg J.S., Denburg J.A. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997, 3:377-386.
79. Asherson R.A., Mercey D., Phillips G., Sheehan N., Gharavi A.E., Harris E.N., et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987, 46:605-611.
80. Caronti B., Calderaro C., Alessandri C., Conti F., Tinghino R., Pini C., et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998, 11:425-429.
81. Caronti B., Pittoni V., Palladini G., Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998, 156:211-219.
82. Olazarán J., López-Longo J., Cruz I., Bittini A., Carreño L. Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates. Eur Neurol 2009, 62:49-55.
83. Menon S., Jameson-Shortall E., Newman S.P., Hall-Craggs M.R., Chinn R., Isenberg D.A. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999, 42:735-741.
84. Whitelaw D.A., Spangenberg J.J., Rickman R., Hugo F.H., Roberts M. The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus 1999, 8:444-448.
85. Schmidt R., uer-Grumbach P., Fazekas F., Offenbacher H., Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke 1995, 26:749-754.
86. Tektonidou M.G., Varsou N., Kotoulas G., Antoniou A., Moutsopoulos H.M. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006, 166:2278-2284.
87. Kao C.H., Lan J.L., Hsieh J.F., Ho Y.J., ChangLai S.P., Lee J.K., et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nucl Med 1999, 40:1446-1450.
88. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007, 36:297-315.
89. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997, 100:613-619.
90. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004, 11:67-75.
91. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
92. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
93. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
94. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
95. Levine S.R., Joseph R., D'Andrea G., Welch K.M. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987, 7:93-99.
96. Alarcon-Segovia D., Deleze M., Oria C.V., Sanchez-Guerrero J., Gomez-Pacheco L., Cabiedes J., et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989, 68:353-365.
97. Montalban J., Cervera R., Font J., Ordi J., Vianna J., Haga H.J., et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992, 42:681-682.
98. Verrotti A., Cieri F., Pelliccia P., Morgese G., Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res 2000, 30:109-111.
99. Cuadrado M.J., Khamashta M.A., Hughes G.R. Migraine and stroke in young women. QJM 2000, 93:317-318.
100. Tietjen G.E., Day M., Norris L., Aurora S., Halvorsen A., Schultz L.R., et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology 1998, 50:1433-1440.
101. Sanna G., Bertolaccini M.L., Cuadrado M.J., Khamashta M.A., Hughes G.R. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003, 42:200-213.
102. Stojanovich L., Zandman-Goddard G., Pavlovich S., Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007, 6:421-426.
103. Vargas-Alarcon G., Yamamoto-Furusho J.K., Zuniga J., Canoso R., Granados J. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). J Autoimmun 1997, 10:579-583.
104. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry 2003, 25:27-33.
105. Schwartz M., Rochas M., Weller B., Sheinkman A., Tal I., Golan D., et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998, 59:20-23.
106. Janavs J.L., Aminoff M.J. Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 1998, 65:436-445.
107. Amital H., Langevitz P., Levy Y., Afek A., Goldberg I., Pras M., et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999, 17:99-102.
108. Klawans H.L., Weiner W.J. The pharmacology of choreatic movement disorders. Prog Neurobiol 1976, 6:49-80.
109. Cervera R., Asherson R.A., Font J., Tikly M., Pallares L., Chamorro A., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997, 76:203-212.
110. Wiechens B., Schroder J.O., Potzsch B., Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997, 123:848-850.
111. Nahum A., Levy Y., Shoenfeld Y. Ocular manifestations in the antiphospholipid syndrome. Harefuah 1999, 136:50-53.
112. Gibbs A.N., Moroney J., Foley-Nolan D., O'Connell P.G. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford) 2002, 41:470-471.
113. Giorgi D., Gabrieli C.B., Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm 1998, 6:269-273.
114. Reino S., Munoz-Rodriguez F.J., Cervera R., Espinosa G., Font J., Ingelmo M. Optic neuropathy in the "primary" antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol 1997, 16:629-631.
115. Giorgi D., Balacco G.C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999, 18:124-131.
116. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000, 79:57-68.
117. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
118. Karussis D., Leker R.R., Ashkenazi A., Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol 1998, 44:629-634.
119. Tourbah A., Clapin A., Gout O., Fontaine B., Liblau R., Batteux F., et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998, 55:517-521.
120. Bidot C.J., Horstman L.L., Jy W., Jimenez J.J., Bidot C., Ahn Y.S., et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol 2007, 7:36.
121. Berman M., Feldman S., Alter M., Zilber N., Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981, 31:966-971.
122. Kovacs B., Lafferty T.L., Brent L.H., DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000, 59:120-124.
123. Lavalle C., Pizarro S., Drenkard C., Sanchez-Guerrero J., Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990, 17:34-37.
124. Ruiz-Arguelles G.J., Guzman-Ramos J., Flores-Flores J., Garay-Martinez J. Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus 1998, 7:49-50.
125. Lavalle C., Pizarro S., Drenkard C., Sanchez-Guerrero J., Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990, 17:34-37.
126. Shin S.Y., Lee J.M. A case of multiple cranial nerve palsies as the initial ophthalmic presentation of antiphospholipid syndrome. Korean J Ophthalmol 2006, 20:76-78.
127. Falcini F., Taccetti G., Trapani S., Tafi L., Petralli S., Matucci-Cerinic M. Primary antiphospholipid syndrome: a report of two pediatric cases. J Rheumatol 1991, 18:1085-1087.
128. Kesler A., Ellis M.H., Reshef T., Kott E., Gadoth N. Idiopathic intracranial hypertension and anticardiolipin antibodies. J Neurol Neurosurg Psychiatry 2000, 68:379-380.
129. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:401S-428S.
130. Wardlaw J.M., del Z.G., Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2000, CD000213.
131. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
132. Mohr J.P., Thompson J.L., Lazar R.M., Levin B., Sacco R.L., Furie K.L., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444-1451.
133. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295:1050-1057.
134. Roldan J.F., Brey R.L. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2007, 9:109-115.
135. Alarcon-Segovia D., Boffa M.C., Branch W., Cervera R., Gharavi A., Khamashta M., et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003, 12:499-503.
136. Roubey R.A. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003, 48:3004-3008.
137. Espinola R.G., Pierangeli S.S., Gharavi A.E., Harris E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87:518-522.
138. Napoleone E., Di S.A., Camera M., Tremoli E., Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000, 86:139-143.
139. Blank M., Anafi L., Zandman-Goddard G., Krause I., Goldman S., Shalev E., et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007, 19:857-865.
140. Hsiao G.R., Wolf R.E., Kimpel D.L. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 2001, 7:336-339.
141. Chang P., Millar D., Tsang P., Lim K., Houlihan E., Stephenson M. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol 2006, 23:125-129.
142. Carp H.J., Sapir T., Shoenfeld Y. Intravenous immunoglobulin and recurrent pregnancy loss. Clin Rev Allergy Immunol 2005, 29:327-332.
143. Konova E. Intravenous immunoglobulin therapy in antiphospholipid syndrome. Clin Rev Allergy Immunol 2005, 29:229-236.
144. Arabshahi B., Thompson E.D., Smergel E.M., Goldsmith D.P. Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report. Clin Rheumatol 2007, 26:251-253.
145. Shoenfeld Y., Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005, 38:123-137.
146. Roberts J.R., Finger D.R. Catastrophic antiphospholipid syndrome; a "CATASTROPHIC" case of systemic lupus erythematosus. Hawaii Med J 2004, 63:362-364.
147. McIntyre J.A. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation-reduction reactions. Thromb Res 2004, 114:579-587.
148. Triolo G., Ferrante A., Accardo-Palumbo A., Ciccia F., Cadelo M., Castelli A., et al. IVIG in APS pregnancy. Lupus 2004, 13:731-735.
149. Horn H.C., Grau K., Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus 2004, 13:478-480.
150. Tincani A., Branch W., Levy R.A., Piette J.C., Carp H., Rai R.S., et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003, 12:524-529.
151. Sherer Y., Wu R., Kraus I., Peter J.B., Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus 2001, 10:568-570.
152. Vinatier D., Dufour P., Cosson M., Houpeau J.L. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2001, 96:37-50.
153. Sherer Y., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 2000, 39:421-426.
154. Asherson R.A. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998, 7(Suppl 2):S55-S62.
155. Krause I., Blank M., Shoenfeld Y. Immunomodulation of experimental APS: lessons from murine models. Lupus 1996, 5:458-462.
156. Krause I., Blank M., Levi Y., Koike T., Barak V., Shoenfeld Y. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999, 117:190-197.
157. Krause I., Blank M., Shoenfeld Y. Treatment of systemic lupus erythematosus and antiphospholipid syndrome: from experimental models to patients' bedside. Int Arch Allergy Immunol 1996, 111:355-361.
158. Erre G.L., Pardini S., Faedda R., Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008, 17:50-55.
159. Pierangeli S.S., Blank M., Liu X., Espinola R., Fridkin M., Ostertag M.V., et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun 2004, 22:217-225.
160. Wang M.X., Kandiah D.A., Ichikawa K., Khamashta M., Hughes G., Koike T., et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995, 155:1629-1636.
161. Muscal E., Brey R.L. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008, 10:67-73.
162. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
163. Tarr T., Lakos G., Bhattoa H.P., Soltesz P., Shoenfeld Y., Szegedi G., et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007, 32:131-137.
164. Saidi S., Mahjoub T., Almawi W.Y. Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost 2009 Apr 24, [Epub ahead of print].
165. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
166. Levine S.R., Deegan M.J., Futrell N., Welch K.M. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990, 40:1181-1189.
167. Nahum A., Levy Y., Shoenfeld Y. Ocular manifestations in the antiphospholipid syndrome. Harefuah 1999, 136:50-53.
168. Wiechens B., Schroder J.O., Potzsch B., Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997, 123:848-850.
169. Gibbs A.N., Moroney J., Foley-Nolan D., O'Connell P.G. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford) 2002, 41:470-471.
170. Giorgi D., Gabrieli C.B., Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm 1998, 6:269-273.
171. Reino S., Munoz-Rodriguez F.J., Cervera R., Espinosa G., Font J., Ingelmo M. Optic neuropathy in the "primary" antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol 1997, 16:629-631.
172. Yehudai D., Shoenfeld Y., Toubi E. Looking into the eyes of patients with antiphospholipid syndrome. Clin Rev Allergy Immunol 2007, 32:192-197.
173. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003, 79:81-83.
174. Levine S.R., Joseph R., D'Andrea G., Welch K.M. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987, 7:93-99.
175. Hughes G. Hughes Syndrome: the antiphospholipid syndrome-a clinical overview. Clin Rev Allergy Immunol 2007, 32:3-12.
176. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von L.P., et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004, 31:1344-1348.
177. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997, 28:1660-1665.
178. Sanna G., D'Cruz D., Cuadrado M.J. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006, 32:465-490.
179. Eriksson K., Peltola J., Keranen T., Haapala A.M., Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001, 46:129-137.
180. Verrot D., San-Marco M., Dravet C., Genton P., Disdier P., Bolla G., et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997, 103:33-37.
181. Chapman J., Soloveichick L., Shavit S., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol 2005, 12:175-180.
182. Cervera R., Asherson R.A., Font J., Tikly M., Pallares L., Chamorro A., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997, 76:203-212.
183. Tektonidou M.G., Varsou N., Kotoulas G., Antoniou A., Moutsopoulos H.M. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006, 166:2278-2284.
184. Kao C.H., Lan J.L., Hsieh J.F., Ho Y.J., ChangLai S.P., Lee J.K., et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nucl Med 1999, 40:1446-1450.
185. Shoenfeld Y., Twig G., Katz U., Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008, 30:74-83.
186. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997, 100:613-619.
187. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004, 11:67-75.
188. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000, 11:36-38.
189. Juby A., Davis P., Genge T., McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 1995, 4:482-485.
190. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
191. Menon S., Jameson-Shortall E., Newman S.P., Hall-Craggs M.R., Chinn R., Isenberg D.A. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999, 42:735-741.
192. Katzav A., Faust-Socher A., Kvapil F., Michaelson D.M., Blank M., Pick C.G., et al. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging 2009 Mar 10, [Epub ahead of print].
193. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
194. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997, 100:613-619.
195. Colasanti T., Delunardo F., Margutti P., Vacirca D., Piro E., Siracusano A., et al. Autoantibodies involved in neuropsychiatric manifestations associated with Systemic Lupus Erythematosus. J Neuroimmunol 2009 Jun 3, [Epub ahead of print].
196. Schwartz M., Rochas M., Weller B., Sheinkman A., Tal I., Golan D., et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998, 59:20-23.
197. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis?. Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000, 79:57-68.
198. Karussis D., Leker R.R., Ashkenazi A., Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol 1998, 44:629-634.
199. Tourbah A., Clapin A., Gout O., Fontaine B., Liblau R., Batteux F., et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998, 55:517-521.
200. Lavalle C., Pizarro S., Drenkard C., Sanchez-Guerrero J., Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990, 17:34-37.
201. Mortifee P.R., Bebb R.A., Stein H. Communicating hydrocephalus in systemic lupus erythematosus with antiphospholipid antibody syndrome. J Rheumatol 1992, 19:1299-1302.
202. Shin S.Y., Lee J.M. A case of multiple cranial nerve palsies as the initial ophthalmic presentation of antiphospholipid syndrome. Korean J Ophthalmol 2006, 20:76-78.
203. Falcini F., Taccetti G., Trapani S., Tafi L., Petralli S., Matucci-Cerinic M. Primary antiphospholipid syndrome: a report of two pediatric cases. J Rheumatol 1991, 18:1085-1087.
204. Miesbach W., Gilzinger A., Gokpinar B., Claus D., Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg 2006, 108:135-142.